EyePoint Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1987-01-01
- Employees
- 121
- Market Cap
- $486.4M
- Introduction
EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.
Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019
- Conditions
- Acute Respiratory Distress Syndrome (ARDS)COVID-19
- Interventions
- Drug: Razuprotafib Subcutaneous SolutionDrug: Placebo Subcutaneous Solution
- First Posted Date
- 2020-08-13
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- EyePoint Pharmaceuticals, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT04511650
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸University of Cincinnati, Cincinnati, Ohio, United States
Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma
- Conditions
- Primary Open Angle GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2020-05-28
- Last Posted Date
- 2023-05-25
- Lead Sponsor
- EyePoint Pharmaceuticals, Inc.
- Target Recruit Count
- 194
- Registration Number
- NCT04405245
- Locations
- 🇺🇸
Kannarr Eye Care, Pittsburg, Kansas, United States
🇺🇸Heart of America Eye Care, P.A., Shawnee Mission, Kansas, United States
🇺🇸Shettle Eye Research, Largo, Florida, United States
DEXYCU (Dexamethasone Intraocular Suspension) 9% Retrospective Study 001
- Conditions
- Cataract
- Interventions
- Drug: DEXYCU (dexamethasone intraocular suspension) 9%.
- First Posted Date
- 2020-03-02
- Last Posted Date
- 2021-05-26
- Lead Sponsor
- EyePoint Pharmaceuticals, Inc.
- Target Recruit Count
- 527
- Registration Number
- NCT04290676
- Locations
- 🇺🇸
Inland Eye Specialists, Hemet, California, United States
🇺🇸Harvard Eye Associates, Laguna Hills, California, United States
🇺🇸Coastal Vision Medical Group, Orange, California, United States
The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
- Conditions
- Nonproliferative Diabetic Retinopathy
- Interventions
- Drug: AKB-9778Drug: Placebo
- First Posted Date
- 2017-06-23
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- EyePoint Pharmaceuticals, Inc.
- Target Recruit Count
- 167
- Registration Number
- NCT03197870
- Locations
- 🇺🇸
Retina Consultants of Orange County, Fullerton, California, United States
🇺🇸Southeast Retina Center, Augusta, Georgia, United States
🇺🇸Georgia Retina, Marietta, Georgia, United States
Utilization and Safety of the Mk II Inserter and the Safety of the FAI Insert in Non-Infectious Uveitis
- Conditions
- Non-Infectious Uveitis
- Interventions
- Drug: FAI Insert administered using the Mk II inserterDrug: FAI Insert administered using the Mk I inserter
- First Posted Date
- 2016-04-22
- Last Posted Date
- 2020-05-01
- Lead Sponsor
- EyePoint Pharmaceuticals, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT02748512
- Locations
- 🇺🇸
Charleston Neuroscience Institute, Ladson, South Carolina, United States
🇺🇸Massachusetts Eye Research and Surgery Institution / Ocular Immunology & Uveitis Foundation, Waltham, Massachusetts, United States
🇺🇸Duke Eye Center, Durham, North Carolina, United States
Safety and Efficacy Study of a FAI Insert in Subjects With Chronic Non-infectious Posterior Uveitis
- Conditions
- Posterior UveitisIntermediate UveitisPanuveitis
- Interventions
- Drug: FAI InsertDrug: Sham Injection
- First Posted Date
- 2016-04-21
- Last Posted Date
- 2020-07-21
- Lead Sponsor
- EyePoint Pharmaceuticals, Inc.
- Target Recruit Count
- 153
- Registration Number
- NCT02746991
- Locations
- 🇮🇳
PBMA'S, H. V. Desai Eye Hospital, Pune, Maharashtra, India
🇮🇳King George's Medical University, Lucknow, Uttar Pradesh, India
🇮🇳C.H. Nagri Municipal Eye Hospital, Ahmedabad, Gujarat, India
Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert
- Conditions
- Non-Infectious Uveitis
- Interventions
- Drug: Sham injectionDrug: FAI insert
- First Posted Date
- 2012-09-27
- Last Posted Date
- 2021-04-02
- Lead Sponsor
- EyePoint Pharmaceuticals, Inc.
- Target Recruit Count
- 129
- Registration Number
- NCT01694186
- Locations
- 🇮🇳
PBMA'S H.V. Desai Eye Hospital, Hadapsar, Pune, India
🇺🇸Retina Macula Institute, Torrance, California, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States